The important announcements for Hong Kong stocks today are as follows:

1) Company News

$SF HOLDING (06936.HK)$In November, the express Logistics business, supply chain, and international business had a total revenue of 25.196 billion yuan, a year-on-year increase of 6.73%.

Due to the earlier promotional period of the e-commerce platform's Singles' Day Sales, this year's peak season for express delivery began in October, earlier than last year. Looking at the cumulative data from October to November, the company's express logistics revenue increased by 7.85% year-on-year, and the volume of business grew by 16.84% year-on-year.

Benefiting from the high level of international shipping freight rates and stable cargo volumes, as well as increased demand for international air transportation, brought about significant year-on-year growth in international freight and agency business income; in November, the revenue from supply chain and international business increased by 21.65% year-on-year.

$WUXI APPTEC (02359.HK)$A total of 20 million euros is planned to be invested in subscribing to private equity Fund shares. The Fund focuses on biotechnology companies in Europe and seed investment activities, targeting startups in the mature and growth stages.

The announcement states that the fund manager, Sofinnova Partners, is a well-known biotechnology investment institution in Europe, with over 50 years of industry resources and investment management experience in the European life sciences sector.

$LIANLIAN (02598.HK)$: Obtained a license for operating a virtual asset trading platform in Hong Kong.

$GOLDWIND (02208.HK)$: A subsidiary intends to transfer 100% equity of Muniushan Holdings.

$JLMAG (06680.HK)$A proposed discount of approximately 10.2% for the placement of no more than 6.7238 million shares, raising about 51.22 million Hong Kong dollars.

$HENLIUS (02696.HK)$Regarding the cooperation and licensing agreement with PALLEON for E-602 and combination therapy.

$SSY GROUP (02005.HK)$A framework agreement was signed with Junsheng Tai Pharmaceutical for joint research and development.

$TYK MEDICINES-B (02410.HK)$The China Securities Regulatory Commission issued a filing notice regarding the company's application for full circulation of H shares.

$SINO BIOPHARM (01177.HK)$The application for marketing authorization for the combination of Bemocizumab injection and Anlotinib hydrochloride capsules in the treatment of advanced alveolar soft part sarcoma has been approved for submission.

2) Buyback dynamics

$TIMES ELECTRIC (03898.HK)$The cancellation of 4.8873 million H shares that have been repurchased.

$AIA (01299.HK)$Invested 0.252 billion Hong Kong dollars to repurchase 4.6258 million shares at a price of 54.15-54.75 Hong Kong dollars.

$TENCENT (00700.HK)$Invested 0.703 billion Hong Kong dollars to repurchase 1.72 million shares at a price of 401.4-421.8 Hong Kong dollars.

$CSPC PHARMA (01093.HK)$Invested 29.294 million Hong Kong dollars to repurchase 6.15 million shares at a repurchase price of 4.72-4.79 Hong Kong dollars.

$SAMSONITE (01910.HK)$Invested 16.2702 million Hong Kong dollars to repurchase 0.7737 million shares at a repurchase price of 20.8-21.2 Hong Kong dollars.

Editor/danial